Reduction of acid exposure and regression of Barrett's esophagus

Digestive Diseases

Volumn 18, Issue 4, 2001, Pages 203-207

  Sampliner, Richard E ^a,b  

^a SOUTHERN ARIZONA VA HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF ARIZONA   (United States)

Author keywords

Barrett's esophagus; Gastroesophageal reflux; Proton pump inhibitors

Indexed keywords

HISTAMINE H2 RECEPTOR ANTAGONIST; LANSOPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR;

ADENOCARCINOMA; ANTIREFLUX OPERATION; BARRETT ESOPHAGUS; CANCER RISK; CLINICAL TRIAL; CONFERENCE PAPER; ESOPHAGITIS; ESOPHAGOSCOPY; ESOPHAGUS CANCER; HUMAN; INTESTINE METAPLASIA; PRIORITY JOURNAL; REMISSION; STOMACH ACID;

ANTI-ULCER AGENTS; BARRETT ESOPHAGUS; ESOPHAGUS; GASTROESOPHAGEAL REFLUX; HUMANS; OMEPRAZOLE; PROTON PUMPS;

EID: 0343462327     PISSN: 02572753     EISSN: None     Source Type: Journal    
DOI: 10.1159/000051400     Document Type: Conference Paper

References (18)

1. Sharma P, Morales TG, Bhattacharyya A, Garewal HS, Sampliner RE: Squamous islands in Barrett's esophagus: What lies underneath? Am J Gastroenterol 1998;93:332-335.
2. Sharma P, Bhattacharyya A, Garewal HS, Sampliner RE: Durability of new squamous epithelium after endoscopic reversal of Barrett's esophagus. Gastrointest Endosc 1999;50: 159-164.
3. Van Laethem JL, Peny MO, Salmon I, Cremer M, Deviere J: Intramucosal adenocarcinoma arising under squamous re-epithelialisation of Barrett's oesaphagus. Gut 2000;46:574-577.
4. Sampliner RE, Fass R: Partial regression of Barrett's esophagus - An inadequate endpoint. Am J Gastroenterol 1993;88:2092-2094.
5. Cameron A, Lomboy C: Barrett's esophagus: Age, prevalence, and extent of columnar epithelium. Gastroenterology 1992;103:1241-1245.
6. Kim R. Baggott B, Rose S, Shar A, Mallory D, Lasky SS, Kressloff M, Faccenda LY, Reynolds JC: Quantitative endoscopy: Precise computerized measurement of metaplastic epithelial surface area in Barrett's esophagus. Gastroenterology 1995;108:360-366.
7. Cooper BT, Barbezat GO: Treatment of Barrett's esophagus with H2 blockers. J Clin Gastroenterol 1987;9:1391-41.
8. Sampliner RE, Garewal HS, Fennerty MB, Aickin M: Lack of impact of therapy on extent of Barrett's esophagus in 67 patients. Dig Dis Sci 1990;35:93-96.
9. Neumann C, Iqbal T, Cooper B: Long term continuous omeprazole treatment of patients with Barrett's oesophagus. Aliment Pharmacol Ther 1995;9:451-454.
10. Cooper BT, Neumann CS, Cox MA, Iqbal TH: Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. Aliment Pharmacol Ther 1998;12:893-897.
11. Gore S, Healey CJ, Sutton R, Eyre-Brook IA, Gear MW, Shepherd NA, Wilkinson SP: Regression of columnar lined (Barrett's) oesophagus with continuous omeprazole therapy. Aliment Pharmacol Ther 1993;7:623-628.
12. Wilkinson SP, Biddlestone L, Gore S, Shepherd NA: Regression of columnar-lined (Barrett's) oesophagus with omeprazole 40 mg daily: Results of 5 years of continuous therapy. Aliment Pharmacol Ther 1999;13:1205-1209.
13. Malesci A, Savarino V. Zentilin P, Belicchi M, Mela G, Lapertosa G, Bocchia P, Ronchi G, Franceschi M: Partial regression of Barrett's esophagus by long-term therapy with high-dose omeprazole. Gastrointest Endosc 1996;44: 700-705.
14. Sharma P, Sampliner RE, Camargo E: Normalization of esophageal pH with high-dose proton pump inhibitor therapy does not result in regression of Barrett's esophagus. Am J Gastroenterol 1997;92:582-585.
15. Sampliner RE: Effect of up to 3 years of high-dose lansoprazole on Barrett's esophagus. Am J Gastroenterol 1994;89:1844-1848.
16. Peters F, Ganesh S, Kuipers E, Sluiter W, Klinkenberg-Knol E, Lamers C, Kleibeuker J: Endoscopic regression of Barrett's oesophagus during omeprazole treatment: A randomised double blind study. Gut 1999;45:489-494.
17. Fass R, Sampliner RE, Malagon IB, Hayden C, Camargo L, Wendel C, Garewal H: Failure of oesophagcal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor. Aliment Pharmacol Ther 2000;14:597-602.
18. Devesa SS, Blot WJ, Fraumeni JF Jr: Changing patterns in the incidence of esophageal and gastric carcinoma in the United States. Cancer 1998;83:2049-2053.